Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Pneumonia; Dyspnoea; This is a spontaneous report downloaded from the regulatory authority-WEB NL-LRB-00460560. A contactable physician reported that a 87-years-old female patient started to receive bnt162b2 (COMIRNATY), via an unspecified route of administration on 18Feb2021 at 1 DF, single for covid-19 immunisation. The patient medical history was not reported. Concomitant medication included gliclazide (GLICLAZIDE), macrogol (MACROGOL), temazepam (TEMAZEPAM), calciumcarbonaat (CALCIUMCARBONAAT), enalapril (ENALAPRIL), metformin (METFORMIN). The patient experienced dyspnoea on 22Feb2021, pneumonia on an unspecified date on 25Feb2021. The patient died from the events on an unknown date. It was not reported if an autopsy was performed. Dyspnoea started 4 days after vaccination, 7 days after vaccination the dyspnoea worsened and the patient developed pneumonia. The decision was made to not treat the pneumonia and to start palliative sedation. No follow-up attempts are possible; information about lot/batch number cannot be obtained; Reported Cause(s) of Death: Dyspnea; pneumonie
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166